STOCK TITAN

Wellington Group reports 4.3% Zai Lab (ZLAB) stake on amended 13G

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Wellington Management Group LLP and related entities reported their beneficial ownership of Zai Lab Ltd. common stock on an amended Schedule 13G. They disclose beneficial ownership of 48,112,590 shares, representing 4.3% of the outstanding common stock, with no sole voting or dispositive power.

The filing states that all securities are held in the ordinary course of business for advisory clients of Wellington’s investment advisers. It also certifies that the holdings were not acquired, and are not held, for the purpose of changing or influencing control of Zai Lab.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:02/10/2026

FAQ

What percentage of Zai Lab (ZLAB) does Wellington report owning in this Schedule 13G/A?

Wellington and its related entities report beneficial ownership of 4.3% of Zai Lab’s common stock. This stake, disclosed on an amended Schedule 13G, reflects institutional investment holdings managed on behalf of advisory clients rather than a control-seeking position.

How many Zai Lab (ZLAB) shares does Wellington beneficially own according to the filing?

The filing states that Wellington and its affiliates beneficially own 48,112,590 Zai Lab common shares. These shares are held for clients of Wellington investment advisers, who have rights to dividends and sale proceeds, while Wellington reports shared voting and dispositive power.

Does Wellington seek to influence control of Zai Lab (ZLAB) with this ownership?

No. Wellington certifies the Zai Lab shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company, consistent with a passive institutional investment reported on Schedule 13G.

Who are the reporting persons in the Zai Lab (ZLAB) Schedule 13G/A amendment?

The reporting persons are Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP. They report ownership through various Wellington investment advisers whose clients hold Zai Lab shares and receive dividends and sale proceeds.

What voting and dispositive powers does Wellington report over Zai Lab (ZLAB) shares?

Wellington reports no sole voting or dispositive power over Zai Lab shares, but shared voting power over 46,641,240 shares and shared dispositive power over 48,112,590 shares. These powers are exercised in connection with managing client accounts invested in Zai Lab stock.

Why is this Zai Lab (ZLAB) Schedule 13G/A classified as owning 5 percent or less?

Item 5 states that Wellington’s beneficial ownership is 5 percent or less of the class. With a 4.3% reported stake, the filing confirms that neither Wellington nor any single underlying client has more than five percent of Zai Lab’s outstanding common stock.
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Latest SEC Filings

ZLAB Stock Data

2.07B
106.96M
1.74%
42.53%
4.26%
Biotechnology
Pharmaceutical Preparations
Link
China
SHANGHAI